Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 12/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.50 |
| ▸ | PNP | P00491 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20782416 | 0.79 | HPRT1 (0.65) | HPRT1PNPADORA2AADORA1 | |
| SCHEMBL8791177 | 0.78 | HPRT1 (0.51) | HPRT1PNPALDH1A1 | |
| SCHEMBL13145301 | 0.78 | HPRT1 (0.51) | HPRT1PNPALDH1A1 | |
| SCHEMBL21362204 | 0.78 | HPRT1 (0.51) | HPRT1PNPALDH1A1 | |
| SCHEMBL24667516 | 0.78 | HPRT1 (0.48) | HPRT1PNPALDH1A1 | |
| SCHEMBL21137628 | 0.78 | HPRT1 (0.49) | HPRT1PNPALDH1A1 | |
| SCHEMBL13657243 | 0.78 | PI4KA (0.51) | HPRT1PNPALDH1A1 | |
| SCHEMBL1993930 | 0.78 | HPRT1 (0.63) | HPRT1PNPADORA2AADORA1 | |
| SCHEMBL784333 | 0.78 | ADORA2A (0.51) | HPRT1PNPALDH1A1ADORA2AADORA1 | |
| SCHEMBL16276016 | 0.77 | HPRT1 (0.50) | HPRT1PNPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037636-B2 | Polynucleotide synthesis method, kit and system | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-07-16 | — | — | US | disclosed |
| US-12037636-B2 | Polynucleotide synthesis method, kit and system | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-07-16 | — | — | US | disclosed |
| WO-2024119117-A1 | MODIFIED 5' CAP FOR MRNA AND METHODS OF USE THEREOF | PRIME MEDICINE, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024006804-A2 | METHODS OF ADMINISTERING A STING AGONIST | LONZA SALES AG (CH) | 2024-01-04 | — | — | WO | disclosed |
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| EP-3728283-B1 | 3'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
| US-20070026397-A1 | Method for producing second-generation library | NUEVOLUTION A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| US-20070026397-A1 | Method for producing second-generation library | NUEVOLUTION A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| WO-2000068230-A1 | 9-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)-1,9-DIHYDROPURIN-6-ONE DERIVATIVES AS PDE7 INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
| US-6121296-A | ADMINISTERING TO TREAT PARASITIC INFECTION OR DISEASE OR TO TREAT INFECTIONS AND DISEASES CAUSED BY CERTAIN BACTERIAL AND PLANT TOXINS; COMPOUNDS SUCH AS SALT OF 2-PHENYL-3,4-DIHYDROXY-5-HYDROXYMETHYL-PYRROLIDINE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0383759-B1 | N6 SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | DISCOVERY THERAPEUTICS INC (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0383759-A4 | N?6 -SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | — | 1993-03-17 | — | — | EP | disclosed |
| US-5066655-A | Inhibiting adenylate cyclase | WHITBY RESEARCH, INC. (US) | 1991-11-19 | — | — | US | disclosed |
| EP-0383759-A1 | N6 SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | Whitby Research Incorporated (US) | 1990-08-29 | — | — | EP | disclosed |
| WO-1988008303-A1 | N6-SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1988-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | HPRT1 16/4885PIK3CG 2668/4885PIK3C3 3788/4885 |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALK, DGKG, EIF2AK2 | HPRT1 3881/4885PIK3CG 188/4885PIK3C3 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.